2023-11-20

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF IMM2510 FOR THE TREATMENT OF ASPS

2023-11-08

VOLUNTARY ANNOUNCEMENT - ORPHAN-DRUG DESIGNATION FROM FDA IN RESPECT OF COMBINATION OF IMM01 AND AZACITIDINE FOR THE TREATMENT OF CMML

2023-11-07

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE II CLINICAL TRIAL OF IMM2510

2023-11-06

VOLUNTARY ANNOUNCEMENT - PRESENTATIONS OF PHASE II RESEARCH STUDIES OF IMM01 AT THE 2023 ASH ANNUAL MEETING

2023-11-03

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2023

2023-10-27

ARTICLES OF ASSOCIATION

2023-10-27

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

2023-10-16

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM47

2023-10-06

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2023

2023-10-04

Next Day Disclosure Return

2023-09-28

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

2023-09-27

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM47

2023-09-26

ANNOUNCEMENT INTERIM REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023

2023-09-13

DISCLOSEABLE TRANSACTION - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

2023-09-11

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM2510 AND IMM27M

2023-09-04

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

2023-09-04

TERMS OF REFERENCE OF THE NOMINATION COMMITTEE

2023-09-04

TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE

2023-09-04

TERMS OF REFERENCE OF THE AUDIT COMMITTEE

2023-09-04

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS